 Home > Medical News > Latest Medical News > FDA blockbuster drug approval plan in November 2021

FDA blockbuster drug approval plan in November 2021

 Last Update: 2021-11-15
 Source: Internet
 Author: User

Tags

lice treatment dollar

palmar hyperhidrosis treatment

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Compilenewborn

Since the beginning of this year, the US FDA has approved 41 innovative drugs, and only one was approved in October

It is worth mentioning that Tavneos is the first oral complement 5a receptor (C5aR) inhibitor approved by the US FDA and the first drug approved for the treatment of ANCA-related vasculitis in ten years

Entering November, a number of drugs will usher in an important review decision by the FDA

Reference source: Biotech Stocks Facing FDA Decision In November 2021

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

L-Ascorbate-2-Monophosphate Feed Grade

CAS No.: 109620-90-8

Feed Grade

Potassium Sorbate from reliable manufacturer

CAS No.: 590-00-1

Food Grade

Doxycycline Hydrochloride

CAS No.: 10592-13-9

Pharmaceutical Grade

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.